Short RNA Aptamer for NGF Binding with Reduced Chain Length
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NGF inhibitors, such as antibodies, have limitations in specificity, immune reactions, and delivery issues, and existing aptamers for NGF are too long for practical pharmaceutical use.
Innovation Solution
Development of a short-chain RNA aptamer that binds specifically to NGF, inhibiting its binding to receptors, with a 50% inhibitory concentration of not more than 10 nM, and modified with inverted dT or polyethylene glycol, which does not bind to NT-3 or inhibit BDNF, NT-3, or NT-4/5, and is suitable for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing aptamers for NGF are used, then NGF binding activity is achieved, but the aptamer chain length is too long for practical pharmaceutical use
Solution Approach 1:
The patent extracts only the essential nucleotide sequences required for NGF binding from the original long aptamer. By identifying and isolating the critical binding regions (specific nucleotide sequences that directly interact with NGF), the invention creates a truncated version that maintains binding activity while reducing overall length to a pharmaceutically acceptable range.
Solution Approach 2:
The invention develops shorter aptamer variants that can be more easily synthesized and modified chemically. These shorter sequences serve as practical pharmaceutical candidates that can be produced more efficiently and with better stability characteristics compared to the original long aptamers, even if they require more frequent administration.
2Reliability
If conventional NGF inhibitors like antibodies are used, then NGF binding is inhibited, but immune reactions and delivery issues occur
Solution Approach 1:
The patent replaces antibody-based inhibition mechanisms with aptamer-based inhibition. Aptamers are nucleic acid molecules that can bind to NGF with high affinity and specificity similar to antibodies, but they are not proteins and therefore do not trigger immune responses. This substitution of the inhibiting agent's fundamental nature eliminates the harmful immune reactions associated with conventional antibody therapies.
3Stability of the object's composition
If aptamers are modified with inverted dT or polyethylene glycol, then stability and delivery characteristics are improved, but molecular complexity increases
Solution Approach 1:
The patent creates composite molecular structures by combining aptamer sequences with stabilizing modifications such as inverted dT (deoxythymidine) residues or polyethylene glycol (PEG) chains. These composite structures integrate the NGF-binding functionality of the aptamer with the stability and delivery-enhancing properties of the modifications, achieving improved pharmacological characteristics through material composition rather than structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamer effectively inhibits NGF receptor binding and neurite outgrowth activity, offering a potent and specific therapeutic option for pain and inflammation with improved stability and delivery characteristics.
Implementation Method 1
an aptamer binding to NGF... which binds specifically to NGF, inhibiting its binding to receptors
Data Source
Figure 1
AI summary
Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.